Rep. Julie Johnson Sells Pfizer Inc. (NYSE:PFE) Shares

Representative Julie Johnson (D-Texas) recently sold shares of Pfizer Inc. NYSE: PFE. In a filing disclosed on February 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Pfizer stock on January 15th. The trade occurred in the Representative's "MERRILL LYNCH TAX EFFICIENT CORE" account.

Representative Julie Johnson also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Dell Technologies NYSE: DELL on 1/28/2025.
• Sold $1,001 - $15,000 in shares of PepsiCo NASDAQ: PEP on 1/28/2025.
• Sold $1,001 - $15,000 in shares of Intuit NASDAQ: INTU on 1/28/2025.
• Sold $1,001 - $15,000 in shares of ALLETE NYSE: ALE on 1/28/2025.
• Sold $1,001 - $15,000 in shares of PPG Industries NYSE: PPG on 1/27/2025.
• Purchased $1,001 - $15,000 in shares of Progressive NYSE: PGR on 1/24/2025.
• Purchased $1,001 - $15,000 in shares of The Goldman Sachs Group NYSE: GS on 1/24/2025.
• Sold $1,001 - $15,000 in shares of Chubb NYSE: CB on 1/24/2025.
• Sold $1,001 - $15,000 in shares of Morgan Stanley NYSE: MS on 1/24/2025.
• Purchased $1,001 - $15,000 in shares of Merck & Co., Inc. NYSE: MRK on 1/17/2025.

Pfizer Price Performance

Shares of NYSE:PFE traded down $0.15 during trading on Monday, hitting $25.50. 33,055,417 shares of the company's stock were exchanged, compared to its average volume of 37,577,760. The business's 50-day simple moving average is $26.28 and its 200 day simple moving average is $27.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The company has a market cap of $144.48 billion, a price-to-earnings ratio of 18.08, a PEG ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company's revenue for the quarter was up 24.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.10 earnings per share. As a group, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a $0.43 dividend. This is an increase from Pfizer's previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.75%. Pfizer's dividend payout ratio (DPR) is presently 121.99%.

Insider Transactions at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the business's stock in a transaction dated Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 0.06% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Evercore ISI raised Pfizer to a "strong-buy" rating in a research note on Wednesday, October 30th. Cantor Fitzgerald reiterated an "overweight" rating and set a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. Truist Financial reduced their price target on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research report on Wednesday, December 18th. Guggenheim reiterated a "buy" rating and set a $33.00 price objective on shares of Pfizer in a research report on Monday, February 10th. Finally, Wolfe Research started coverage on shares of Pfizer in a report on Friday, November 15th. They issued an "underperform" rating and a $25.00 target price on the stock. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $31.92.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Swiss National Bank increased its position in Pfizer by 0.6% during the third quarter. Swiss National Bank now owns 16,819,712 shares of the biopharmaceutical company's stock valued at $486,762,000 after acquiring an additional 100,900 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Pfizer by 11.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company's stock valued at $3,766,366,000 after acquiring an additional 12,864,343 shares during the last quarter. Empowered Funds LLC grew its holdings in shares of Pfizer by 80.9% in the third quarter. Empowered Funds LLC now owns 508,256 shares of the biopharmaceutical company's stock worth $14,709,000 after purchasing an additional 227,349 shares during the last quarter. Addison Advisors LLC grew its holdings in shares of Pfizer by 394.2% in the third quarter. Addison Advisors LLC now owns 52,238 shares of the biopharmaceutical company's stock worth $1,512,000 after purchasing an additional 41,668 shares during the last quarter. Finally, KBC Group NV grew its holdings in shares of Pfizer by 26.0% in the third quarter. KBC Group NV now owns 3,105,433 shares of the biopharmaceutical company's stock worth $89,872,000 after purchasing an additional 639,985 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas' 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027. Johnson (Democratic Party) ran for election to the U.S. House to represent Texas' 32nd Congressional District. She won in the general election on November 5, 2024. Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson's career experience includes working as an attorney.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.